Rezolute, Incorporated is a clinical stage biopharmaceutical company working in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. Originally known as AntriaBio, Inc., Rezolute, Incorporated was founded in 2010 and its lead candidate is RZ358 and is a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism. The company also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in the preclinical stage for the treatment of diabetic macular edema.